Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ralph, you couldn't assume V/GV are the oonly treatment option for TG>500.
My secret wish is that whichever BP who was willing to buy AMRN for $30/share pre Dubacle, assume there was such a BP offer on the table, now is willing to come back and offer a BO at a discount price of $15-$20 since Amarin's legal postion has been somewhat clarified a bit this week. BP could still makes lots of money by paying $6B-$8B.
"NEEDS TO INFORM PRACTITIONERS"? What about practitioners don't care even after being informed. Obviously practitioners need some incentives to go that extra miles in order to prescribe V for their patients.
If "doing good for their patients" is a sufficient reason for PRACTITIONERS to prescribe Vascepa to their patients, Vascepa should be a billion dollar drug by now.
AMRN holding up well up .8% with IBB down 2.38%. Karim is the real deal while JT was the emporer with no clothes.
Does it matter since the CAFC opinion has been published and reported everywhere?
I haven't found anything regarding the downgrade. Judging on the pre-market action, that YMB poster is spreading fake news.
Kiwi, did you get your kitchen sink?
JT: Karim, better lucky than good.
Karim: You are bad and unlucky.
Judging on the stock price this morning, looks like the JT discount is gradually being lifted.
Our new EU leader:
https://www.linkedin.com/in/laurentabuaf/?originalSubdomain=uk
I'll take $280/script with minimal rebate in EU than $137/script net in the US.
postes, $527M COH end of Q221 Vs $539M COH end of Q121, i.e. $12M burn despite a $41M increase in inventory from Q1 to Q2. I guess you have to revise down your projected 2021 cash outflow of $150M.
BBI, my doctor prescribe V to me off label:
Dr. George Hall, MD
Internist in New York City, New York
Address: 217 Grand St #401, New York, NY 10013
Phone: (212) 965-1380
Dr Hall or any doctors in his office will prescribe V off label.
“As we end the flu season this year with fewer than 4,000 cases, I want to emphasize that this is one of the mildest flu seasons on record for Pennsylvania,” Acting Secretary Beam said. “The previous season was higher than usual with more than 130,900 cases of flu.
https://www.media.pa.gov/pages/health-details.aspx?newsid=1473
"What would you like to say?". You brought up Japan. Why such a big difference in covid statistics between US and Japan?
So how you protect your family's respiratory pathways from covid-19 virus?
raf, covid-19 virus enters the human body via respiratory pathways. Do you agree? If yes, any protection of respiratotry pathways is going to reduce COVID-19 transmissoon. Why is it so hard to understand? Do you think condom usage can reduce STD transmission? Do you think it's a good idea to wear a bullet proof vest when going to a battle field?
"13k new cases in Japan today"? Compare with USA, that's a relatively small
number. Do you think Olympics play a role in that 13k number?
Hikma Should Face Amarin's Patent Suit, Magistrate Says
Hikma Should Face Amarin's Patent Suit, Magistrate Says
By Adam Lidgett
Law360 (August 3, 2021, 8:54 PM EDT) -- Hikma Pharmaceuticals should not be able to dodge a lawsuit claiming it encouraged doctors to prescribe its generic version of the heart drug Vascepa for uses covered by a series of Amarin patents, a Delaware federal magistrate judge says.
Magistrate Judge Jennifer L. Hall on Tuesday issued a report and recommendation in a lawsuit filed by Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Ltd. and Mochida Pharmaceutical Co. Ltd. alleging that Hikma induced infringement of three patents.
Specifically, Amarin alleged in the so-called "skinny label" case that Hikma induced doctors to infringe the patents by instructing them to use the Hikma generic for the use indications that Amarin patented. Skinny labels allow generic-drug makers to sell versions of drugs that still have some patent protection by carving out those protected indications from their labels.
The magistrate judge disagreed with Hikma's argument that the suit fails to allege a plausible inducement claim against it.
Amarin's claims "plausibly suggest … that Hikma's label and public statements could instruct and/or encourage third parties to use its product for the" indication that Amarin said is covered by the patents at issue, the magistrate judge said. Judge Hall added that Amarin has also plausibly claimed "Hikma both knew and intended that third parties would use its product for that purpose."
"In my view, that is enough," the magistrate judge wrote.
The lawsuit also targeted health insurer Health Net LLC, which Amarin accused of coming up with an "approval and payment process for Amarin's product and Hikma's generic version [that] amounts to active encouragement to use Hikma's generic version for the patented indication." Amarin alleged that amounted to induced infringement, as well.
The magistrate judge said the claims against Health Net should proceed, too.
"Like Hikma, Health Net points out that it has no duty to discourage others' infringement," the magistrate judge said. "While that is true, plaintiffs also allege that Health Net took active steps — including adopting its formulary and prior authorization procedure for icosapent ethyl prescriptions and taking coverage and payment actions — that are alleged to encourage others' infringement."
The Amarin drug has two indications that the U.S. Food and Drug Administration has approved, only one of which is patent protected, according to the magistrate judge.
Hikma's generic was put on the market after getting FDA approval, but that approval was only for the indication that was not patented, according to the magistrate judge.
Vascepa had been the first drug and, according to Amarin, remains the only drug that can treat severe hypertriglyceridemia without increasing bad cholesterol, the company has said.
Amarin reported in regulatory filings that Vascepa netted $427.4 million in sales in 2019, predominantly in the U.S.
Representatives for the parties did not immediately respond to requests for comment.
The patents-at-issue are U.S. Patent Nos. 9,700,537; 8,642,077; and 10,568,861.
Amarin is represented by Jeremy D. Anderson, Elizabeth M. Flanagan, Michael Kane, Deanna J. Reichel and Jonathan E. Singer of Fish & Richardson PC.
Hikma is represented by Dominick T. Gattuso of Heyman Enerio Gattuso & Hirzel LLP and Charles B. Klein, Claire A. Fundakowski, Eimeric Reig-Plessis and Alison M. King of Winston & Strawn LLP.
Health Net is represented by John C. Phillips Jr. and David A. Bilson of Phillips McLaughlin & Hall PA and Don J. Mizerk and Dustin L. Taylor of Husch Blackwell LLP.
The case is Amarin Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc. et al., case number 1:20-cv-01630, in the U.S. District Court for the District of Delaware.
Courtesy of Patc at ivillage,
https://www.investorvillage.com/smbd.asp?mb=2294&mn=8619&pt=msg&mid=22265817
With an incoming new CEO KM and this breaking NJ district court development, do we still need the cooperation of Judge Du to vacate the MARINE patents in order to faciliate a settement between Amarin and Hikma/Dr. Reddy's?
Or KM is blessed!
AMRN wins critical motion in Vascepa patent case against Hikma. AMRN now gets another chance in Court to prove that Hikma is infringing Amarin's patents, and another chance at excluding Hikma's generic Vascepa from the market.
https://twitter.com/PunditPatent/status/1422636546625265666/photo/1
GSK/Teva skinny label case final opinion should be out in the next months or so.
Judge says Amarin 'skinny label' Vascepa suit should proceed, Bloomberg reports,
https://theflyonthewall.com/content_index.php?symbol=amrn&days_back=30&table=none
Rob, that explains the uptick in volume and stock price last 10 minutes.
I assume that's .5g not 5g in the second row.
one, I misunderstood your post. T0 me merger = BO. What you meant was AMRN made an acquisition. No sharholder would want that.
"I don't want to see have happen with AMRN in the coming months and merger is at the top of the list"? I think there are less than five posters who would agree with you. I believe your reduced postion plays a part in your opinion.
I don't think it's customary to issue a press release for management departure other than CEO or CFO.
"Any explanation other than the incompetence of Amarin"?
Incompetence of doctors, insurance companies, CVD patients and even IHUB Amarin board posters.
Amarin: Is It A Buy, Sell, Or Hold? Buy For New Global Expansion:
https://seekingalpha.com/article/4443046-amarin-buy-sell-hold
You have answered your own question. The % threshold does not prove infringement, the TG threshold does.
styles, don't read too much into it. No M&A until sales start to go up. IMO, CG goes after greener pasture after being pass up for the CEO promtion opportunity. It's a loss for AMRN as he and KM are the most qualified among the current managment team.
joma, "Masks don’t work to protect yourself"? Does mask only allow one way flow of air movement? Does condom reduce the chance of contracting STD for ONLY one partner out of the two partners involved?
Despite down in price, AMRN outperforms IBB by a wide margin today.
zman, you forgot JT said he could only do one thing at a time.
raf, I took it back. You are a great Vascepa patient advocate. If every IHUB poster would do what you did when they see their doctors, AMRN wouldn't be sitting at $4.
You might have lost an opportunity to be a Vascepa patient advocate in front of the new doctor.